Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage psychedelic pharma developing novel psilocybin-derived bretisilocin in Phase 2 for depression; first YC-backed psychedelics company competing with COMPASS Pathways.
Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing novel psychedelic-derived compounds for treatment-resistant depression, anxiety, and stress-related psychiatric disorders — pursuing a drug discovery approach that modifies psychedelic molecular structures to optimize therapeutic effects (efficacy, duration) while retaining or modifying the subjective psychedelic experience. Founded by Jonathan Sporn MD, Dalibor Sames PhD, Andrew Kruegel PhD, Jeff Witkin PhD, and Mike Cunningham PhD, Gilgamesh was the first Y Combinator-backed company in the psychedelic therapeutics space.\n\nGilgamesh's lead compound bretisilocin (GM-2505) is a novel psilocybin-derived molecule in Phase 2 clinical trials for major depressive disorder, positioned as a potential best-in-class psychedelic compound with optimized pharmacokinetics. The company's scientific founders from Columbia University brought expertise in psychedelic pharmacology and medicinal chemistry that enables rational drug design rather than simply repurposing existing natural psychedelics like psilocybin. The differentiated compound IP strategy creates defensible pharmaceutical assets rather than relying on natural compound exclusivity.\n\nIn 2025, Gilgamesh competes in the psychedelic medicine market with COMPASS Pathways (psilocybin for treatment-resistant depression, furthest along in clinical trials), Usona Institute (psilocybin non-profit research), MindMed (LSD and MDMA derivatives), and Lykos Therapeutics (MDMA-assisted therapy) for psychedelic-derived psychiatric treatment development. The FDA declined to approve MDMA-assisted therapy in 2024 (Lykos), creating caution around psychedelic clinical timelines, while COMPASS continues Phase 3 trials for psilocybin. Gilgamesh's novel compound approach (not psilocybin itself) provides a distinct regulatory and IP path. The 2025 strategy focuses on Phase 2 data readouts for bretisilocin, building clinical evidence for the compound's differentiated profile, and advancing toward a Phase 3 pivotal trial design.
NYC YC "TurboTax for Medicaid" at $22M total ($18M a16z Series A Jul 2025) with AI + live navigators reducing member churn 15% addressing $50B administrative waste; 12-person team competing with Maximus for Medicaid enrollment technology.
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowitz (a16z) with BoxGroup, and a $4 million seed in November 2023 from YC, BoxGroup, and angel investors including founders of Zocdoc, PillPack, and Cityblock Health — providing Medicaid health plans, providers, and state governments with an AI-powered Medicaid navigation platform that pairs AI automation with live human navigators to guide beneficiaries through enrollment, coverage maintenance, and renewal workflows, reducing member churn by 15% and addressing the $50 billion in administrative waste that the US Medicaid system generates annually. Founded in 2023 by Cydney Kim, Nikita Singareddy, and Ben Wesner, Fortuna Health operates with a 12-person team and has been described as "TurboTax for Medicaid."
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.